← All trials
NCT04041791
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Aug 31, 2019
- Primary completion
- Aug 31, 2021
- Completion date
- Feb 28, 2022
- First posted
- —
- Last posted
- —
- Enrollment
- 4392
- Arms / groups
- 6 / —
- Source
- AACT · ingestion pipeline
Sponsors
- University of OxfordLead sponsor
- University of LondonCollaborator
- University of OxfordReponsible party - principal investigator
- National Institute for Health Research, United KingdomCollaborator
- Wellcome TrustCollaborator
- Medical Research CouncilCollaborator
- University of NairobiCollaborator
- Government of United KingdomCollaborator
- Kenya Ministry of HealthCollaborator
- University of OxfordOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.